| 9.25 -0.05 (-0.54%) | 09-03 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 10.99 |
1-year : | 12.83 |
| Resists | First : | 9.4 |
Second : | 10.99 |
| Pivot price | 8.29 |
|||
| Supports | First : | 7.52 |
Second : | 6.36 |
| MAs | MA(5) : | 8.97 |
MA(20) : | 8.09 |
| MA(100) : | 5.41 |
MA(250) : | 5.87  |
|
| MACD | MACD : | 0.5 |
Signal : | 0.4 |
| %K %D | K(14,3) : | 89.1 |
D(3) : | 89.6 |
| RSI | RSI(14): 69.5 |
|||
| 52-week | High : | 22 | Low : | 0.1 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ ASBP ] has closed below upper band by 5.4%. Bollinger Bands are 21% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 9.42 - 9.46 | 9.46 - 9.48 |
| Low: | 9.01 - 9.05 | 9.05 - 9.09 |
| Close: | 9.18 - 9.25 | 9.25 - 9.31 |
Aspire Biopharma Holdings, Inc. is an emerging pharmaceutical enterprise dedicated to pioneering and commercializing innovative sublingual drug delivery systems within the United States. Its flagship product, Instaprin, is an advanced sublingual aspirin formulation known for being soluble, pH neutral, and rapidly absorbed, making it effective for both cardiovascular emergencies and general pain management. The company is diligently developing a diverse pipeline of orally dissolving formulations. This includes a melatonin-based sleep aid, essential vitamins (D, E, and K), testosterone, and semaglutide. Furthermore, Aspire Biopharma is extending its sublingual development efforts to various therapeutic areas, such as anti-nausea treatments, antipsychotic medications, erectile dysfunction drugs, and seizure control therapies, among others. They are also exploring caffeine products, including a formulation for a single-dose sublingual pre-workout supplement. Established in 2021, the firm's main operational base is situated in Estero, Florida.
Thu, 03 Sep 2026
ASBP - Aspire Biopharma Holdings Inc Volatility & Greeks - Finviz
Fri, 28 Aug 2026
Aspire BioPharma, Inc. (NASDAQ: ASBP) Share Price, ASBP Stock News, ASBP Share Price & Updates - kalkine.ca
Thu, 13 Aug 2026
Aspire Biopharma Holdings, Inc., to Present at Sidoti Virtual Investor Conference August 19th - Yahoo Finance
Wed, 17 Jun 2026
Aspire Biopharma to Present at the Life Sciences Investor Forum on June 25th - GlobeNewswire
Fri, 12 Jun 2026
Biopharma Aspire to buy 100+ year auto supplier DCS for $30M - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 7 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 1.4e+006 (%) |
| Held by Institutions | 1.12e+006 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -24450 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -6.66 |
| Profit Margin | 0 % |
| Operating Margin | -3 % |
| Return on Assets (ttm) | 880.5 % |
| Return on Equity (ttm) | 60.5 % |
| Qtrly Rev. Growth | 32.1 % |
| Gross Profit (p.s.) | 0.01 |
| Sales Per Share | -0.01 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | -1.4 |
| Price to Sales | -6.87275e+007 |
| Price to Cash Flow | 0 |
| Dividend | 79920 |
| Forward Dividend | 101410 |
| Dividend Yield | 864000% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|